ITGAX and neoplasm: As seen in Figure 9, there was no significant difference between CT26/HER2 tumor-bearing and 4T1.2/HER2 tumor-bearing mice with respect to the percentages of CD11b+/Gr-1+ cells, CD11c+/33D1+ cells, CD3+/CD4+ T cells, CD3+/CD8+ T cells and CD4+/FoxP3+ Treg cells in the TDLNs.